Skip to main content
SpringerLink
Log in

STAT Proteins in Cancer

  • Chapter
  • First Online:
STAT Inhibitors in Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 634 Accesses

Abstract

The seven members of the signal transducer and activator of transcription (STAT) family of proteins are transcription factors that are activated in response to, and mediate signaling downstream of, growth factors and cytokines. STATs are dysregulated in a broad range of cancer types. Although the genes that encode STATs are rarely mutated in cancer, constitutive phosphorylation and hence activation of STATs, particularly STAT3, is a common alteration in cancer. STAT3 and STAT5 are considered to play primarily pro-tumorigenic roles in tumor cells and within the tumor microenvironment (TME), while STAT1 has been described as a tumor suppressor (although recent publications have also revealed pro-tumorigenic functions of STAT1). In this chapter, we survey STATs in cancer, providing a general overview of STAT function and regulation in tumor cells and in immune cells within the TME.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rani A, Murphy JJ (2015) STAT5 in cancer and immunity. J Interferon Cytokine Res 36(4):226–237

    Article  PubMed  Google Scholar 

  2. Li HS, Watowich SS (2013) Diversification of dendritic cell subsets: emerging roles for STAT proteins. JAKSTAT 2:e25112

    PubMed  PubMed Central  Google Scholar 

  3. Santos CI, Costa-Pereira AP (2011) Signal transducers and activators of transcription—from cytokine signalling to cancer biology. Biochim Biophys Acta—Rev Cancer 1816:38–49

    Article  CAS  Google Scholar 

  4. Costa-Pereira AP, Bonito NA, Seckl MJ (2011) Dysregulation of Janus kinases and Signal transducers and activators of transcription in cancer. Am J Cancer Res 1:806–816

    Google Scholar 

  5. Dorritie KA, Redner RL, Johnson DE (2014) STAT transcription factors in normal and cancer stem cells. Adv Biol Regul 56:30–44

    Article  CAS  PubMed  Google Scholar 

  6. Xu D, Qu C-K (2008) Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci 13:4925–4932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yang J, Stark GR (2008) Roles of unphosphorylated STATs in signaling. Cell Res 18:443–451

    Article  CAS  PubMed  Google Scholar 

  8. Concha-Benavente F, Srivastava RM, Trivedi S et al (2016) Identification of the cell-intrinsic and extrinsic pathways downstream of EGFR and IFN that induce PD-L1 expression in head and neck cancer. Cancer Res 76:1031–1043

    Article  CAS  PubMed  Google Scholar 

  9. Dimco G, Knight RA, Latchman DS, Stephanou A (2010) STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest. Cell Cycle 9:4638–4649

    Article  CAS  PubMed  Google Scholar 

  10. Quesnelle KM, Boehm AL, Grandis JR (2007) STAT-mediated EGFR signaling in cancer. J Cell Biochem 102:311–319

    Article  CAS  PubMed  Google Scholar 

  11. Wang S, Raven JF, Durbin JE, Koromilas AE (2008) Stat1 phosphorylation determines Ras oncogenicity by regulating p27Kip1. PLoS One 3:1–14

    CAS  Google Scholar 

  12. Ramana CV, Grammatikakis N, Chernov M et al (2000) Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 19:263–272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51

    Article  CAS  PubMed  Google Scholar 

  14. Abroun S, Saki N, Ahmadvand M et al (2015) STATs: an old story, yet mesmerizing. Cell J 17:395–411

    PubMed  PubMed Central  Google Scholar 

  15. Timofeeva OP, Tarasova NI (2012) Alternative ways of modulating JAK-STAT pathway: looking beyond phosphorylation. JAKSTAT 1:274–284

    PubMed  PubMed Central  Google Scholar 

  16. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Böhmer F-D, Friedrich K (2014) Protein tyrosine phosphatases as wardens of STAT signaling. JAKSTAT 3:e28087

    PubMed  PubMed Central  Google Scholar 

  18. Berger A, Sexl V, Valent P, Moriggl R (2014) Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. Oncotarget 5:9564–9576

    Article  PubMed  PubMed Central  Google Scholar 

  19. Buchert M, Burns CJ, Ernst M (2016) Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 35(8):939–951

    Article  CAS  PubMed  Google Scholar 

  20. Barré B, Vigneron A, Perkins N et al (2007) The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 13:4–11

    Article  PubMed  Google Scholar 

  21. Albesiano E, Davis M, See AP et al (2010) Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma. Cancer Res 70:6467–6476

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kujawski M, Kortylewski M, Lee H et al (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:3367–3377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Peyser ND, Du Y, Li H et al (2015) Loss-of-function PTPRD mutations lead to increased STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. PLoS One 10:e0135750

    Article  PubMed  PubMed Central  Google Scholar 

  24. Peyser ND, Freilino M, Wang L et al (2016) Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene 35(9):1163–1169

    Article  CAS  PubMed  Google Scholar 

  25. Chang Q, Bournazou E, Sansone P et al (2013) The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15:848–862

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yoshikawa H, Matsubara K, Qian GS et al (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28:29–35

    CAS  PubMed  Google Scholar 

  27. Meissl K, Macho-Maschler S, Müller M, Strobl B (2015) The good and the bad faces of STAT1 in solid tumours. Cytokine (in press: doi:10.1016/j.cyto.2015.11.011)

    Google Scholar 

  28. Babon JJ, Varghese LN, Nicola NA (2014) Inhibition of IL-6 family cytokines by SOCS3. Semin Immunol 26:13–19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lesina M, Kurkowski MU, Ludes K et al (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19:456–469

    Article  CAS  PubMed  Google Scholar 

  30. Croker BA, Krebs DL, Zhang J-G et al (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4:540–545

    Article  CAS  PubMed  Google Scholar 

  31. Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A (2013) SOCS, inflammation, and cancer. JAKSTAT 2:e24053

    PubMed  PubMed Central  Google Scholar 

  32. Yang J, Liao X, Agarwal MK et al (2007) Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkB. Genes Dev 21:1396–1408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Avalle L, Pensa S, Regis G et al (2012) STAT1 and STAT3 in tumorigenesis. JAKSTAT 1:65–72

    PubMed  PubMed Central  Google Scholar 

  34. Yang J, Chatterjee-Kishore M, Staugaitis SM et al (2005) Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65:939–947

    CAS  PubMed  Google Scholar 

  35. Wang S, Raven JF, Koromilas AE (2010) STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells. Mol Cancer Res 8:798–805

    Article  CAS  PubMed  Google Scholar 

  36. Kharma B, Baba T, Matsumura N et al (2014) STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res 74:6519–6530

    Article  CAS  PubMed  Google Scholar 

  37. Zimmerman MA, Rahman N-T, Yang D et al (2012) Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and Bad and conferring apoptotic resistance. Cancer Res 72:4724–4732

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54:721–728

    Article  CAS  PubMed  Google Scholar 

  39. Ramana CV, Gil MP, Schreiber RD, Stark GR (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23:96–101

    Article  CAS  PubMed  Google Scholar 

  40. Loke P, Allison JP (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 100:5336–5341

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Bellucci R, Martin A, Bommarito D et al (2015) Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 4:e1008824

    Article  PubMed  PubMed Central  Google Scholar 

  42. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499–4506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Hix LM, Karavitis J, Khan MW et al (2013) Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem 288:11676–11688

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Tymoszuk P, Evens H, Marzola V et al (2014) In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. Eur J Immunol 44:2247–2262

    Article  CAS  PubMed  Google Scholar 

  45. Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117:1155–1166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kusmartsev S, Gabrilovich DI (2005) STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174:4880–4891

    Article  CAS  PubMed  Google Scholar 

  48. Bromberg JF, Wrzeszczynska MH, Devgan G et al (1999) Stat3 as an oncogene. Cell 98:295–303

    Article  CAS  PubMed  Google Scholar 

  49. Grandis JR, Drenning SD, Chakraborty A et al (1998) Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102:1385–1392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Grandis JR, Drenning SD, Zeng Q et al (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97:4227–4232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Harada D, Takigawa N, Kiura K (2014) The role of STAT3 in non-small cell lung cancer. Cancers (Basel) 6:708–722

    Article  CAS  Google Scholar 

  52. Xi S, Zhang Q, Dyer KF et al (2003) Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 278:31574–31583

    Article  CAS  PubMed  Google Scholar 

  53. Kiuchi N, Nakajima K, Ichiba M et al (1999) STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 189:63–73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Yu H, Lee H, Herrmann A et al (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14:736–746

    Article  CAS  PubMed  Google Scholar 

  55. Niu G, Wright KL, Huang M et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000–2008

    Article  CAS  PubMed  Google Scholar 

  56. Devarajan E, Huang S (2009) STAT3 as a central regulator of tumor metastases. Curr Mol Med 9:626–633

    Article  CAS  PubMed  Google Scholar 

  57. Fukuda A, Wang SC, Morris JP et al (2011) Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19:441–455

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Teng Y, Ross JL, Cowell JK (2014) The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT 3:e28086

    PubMed  PubMed Central  Google Scholar 

  59. Wendt MK, Balanis N, Carlin CR, Schiemann WP (2014) STAT3 and epithelial–mesenchymal transitions in carcinomas. JAKSTAT 3:e28975

    PubMed  PubMed Central  Google Scholar 

  60. Xiong H, Hong J, Du W et al (2012) Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial–mesenchymal transition. J Biol Chem 287:5819–5832

    Article  CAS  PubMed  Google Scholar 

  61. Cheng GZ, Zhang W, Sun M et al (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 283:14665–14673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Yadav A, Kumar B, Datta J et al (2011) IL-6 promotes head and neck tumor metastasis by inducing epithelial–mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 9:1658–1667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Sen M, Joyce S, Panahandeh M et al (2012) Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 18:4986–4996

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Byers LA, Sen B, Saigal B et al (2009) Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15:6852–6861

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Poli V, Camporeale A (2015) STAT3-mediated metabolic reprograming in cellular transformation and implications for drug resistance. Front Oncol 5:1–9

    Article  Google Scholar 

  66. Lee HJ, Zhuang G, Cao Y et al (2014) Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26:207–221

    Article  CAS  PubMed  Google Scholar 

  67. Wan S, Zhao E, Kryczek I et al (2014) Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147:1393–1404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Lee H, Kumar Pal S, Reckamp K et al (2011) STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol 344:41–59

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Cheng P, Corzo CA, Luetteke N et al (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205:2235–2249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Vasquez-Dunddel D, Pan F (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 123:1580–1589

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Yu J, Wang Y, Yan F et al (2014) Noncanonical NF-kB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol 193:2574–2586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Kortylewski M, Kujawski M, Wang T et al (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314–1321

    Article  CAS  PubMed  Google Scholar 

  73. Park S-J, Nakagawa T, Kitamura H et al (2004) IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173:3844–3854

    Article  CAS  PubMed  Google Scholar 

  74. Nefedova Y, Huang M, Kusmartsev S et al (2004) Hyperactivation of STAT3 Is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 172:464–474

    Article  CAS  PubMed  Google Scholar 

  75. Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54

    Article  PubMed  Google Scholar 

  76. Kryczek I, Wei S, Zou L et al (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178:6730–6733

    Article  CAS  PubMed  Google Scholar 

  77. Kortylewski M, Xin H, Kujawski M et al (2009) Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15:114–123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Zorn E, Nelson EA, Mohseni M et al (2006) IL-2 regulates FOXP3 expression in human CD4 + CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108:1571–1579

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Grange M, Buferne M, Verdeil G et al (2012) Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma. Cancer Res 72:76–87

    Article  CAS  PubMed  Google Scholar 

  80. Morinobu A, Gadina M, Strober W et al (2002) STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci U S A 99:12281–12286

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Yue C, Xu J, Tan Estioko MD et al (2014) Host STAT2/type I interferon axis controls tumor growth. Int J Cancer 126:117–126

    Google Scholar 

  82. Bruns HA, Kaplan MH (2006) The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol 57:245–253

    Article  PubMed  Google Scholar 

  83. Skinnider BF, Kapp U, Mak TW (2002) The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 43:1203–1210

    Article  CAS  PubMed  Google Scholar 

  84. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174:636–645

    Article  CAS  PubMed  Google Scholar 

  85. Kapoor N, Niu J, Saad Y et al (2015) Transcription factors STAT6 and KLF4 implement macrophage polarization via the dual catalytic powers of MCPIP. J Immunol 194:1–13

    Article  Google Scholar 

  86. Sasaki K, Zhao X, Pardee AD et al (2008) Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol 181:104–108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. McCoon PE, Woessner R, Grosskurth S et al. (2015) Clinical and pre-clinical evidence of an immune modulating role for STAT3-targeting ASO AZD9150 and potential to enhance clinical responses to anti-PDL1 therapy. In: AACR 106th Annual Meeting, Philadelphia, PA, 18–22 April 2015

    Google Scholar 

  88. Liu S, Walker SR, Nelson EA et al (2014) Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther 13:1194–1205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Toniolo PA, Liu S, Yeh JE et al (2015) Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. J Immunol 194:3180–3190

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Filippakopoulos P, Qi J, Picaud S et al (2010) Selective inhibition of BET bromodomains. Nature 468:1067–1073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA

    Rachel A. O’Keefe & Jennifer R. Grandis

Authors
  1. Rachel A. O’Keefe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer R. Grandis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer R. Grandis .

Editor information

Editors and Affiliations

  1. School of Medicine, Deakin University, Warun Ponds, Victoria, Australia

    Alister C. Ward

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

O’Keefe, R.A., Grandis, J.R. (2016). STAT Proteins in Cancer. In: Ward, A. (eds) STAT Inhibitors in Cancer. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-42949-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42949-6_2

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-42947-2

  • Online ISBN: 978-3-319-42949-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation